Exploring the interplay between autoimmunity and cancer to find the target therapeutic hotspots

References

• Silink M. Childhood diabetes: a global perspective. Horm Res Paediatr. 2002;57:1–5.
   Google Scholar
• Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010;9:195–199.
   PubMed Web of Science ®Google Scholar
• Bei R, Masuelli L, Palumbo C, et al. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett. 2009;281:8–23.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Egiziano G, Bernatsky S, Shah AA. Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol. 2016;30:53–62.
   PubMed Web of Science ®Google Scholar
• Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32:1119–1136.
   PubMed Web of Science ®Google Scholar
• Alexander MJ, Teitelbaum H. Observation and analysis of a large amplitude mountain wave event over the Antarctic peninsula. J Geophys Res. 2007;112.
   Web of Science ®Google Scholar
• Koike T. The new era of autoimmune disease research. Arthritis Res Ther. 2011;13:113.
   PubMed Web of Science ®Google Scholar
• Brinckerhoff CE. Cancer stem cells (CSCs) in melanoma: there's smoke, but is there fire? J Cell Physiol. 2017;232:2674–2678.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy. Oncol Rep. 2007;17:1121–1126.
   PubMed Web of Science ®Google Scholar
• Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2:90–97.
   PubMedGoogle Scholar
• Sansone F, Mencherini T, Picerno P, et al. Maltodextrin/pectin microparticles by spray drying as carrier for nutraceutical extracts. J Food Eng. 2011;105:468–476.
   Web of Science ®Google Scholar
• Van den Broek MF, Kaegi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781–1790.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci. 1998;95:7556–7561.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148.
   PubMed Web of Science ®Google Scholar
• Ng B, Yang F, Huston DP, et al. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol. 2004;114:1463–1470.
   PubMed Web of Science ®Google Scholar
• Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–6904.
   PubMed Web of Science ®Google Scholar
• Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–1133.
   PubMed Web of Science ®Google Scholar
• Costa N, Pires AE, Gabriel AM, et al. Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients. J Transl Med. 2011;9:P6.
   PubMedGoogle Scholar
• Pylayeva-Gupta Y. Molecular pathways: interleukin-35 in autoimmunity and cancer. Clin Cancer Res. 2016;22:4973–4978.
   PubMed Web of Science ®Google Scholar
• Barbi JJ, Vignali PD, Yu H, et al. The neurotrophic factor neuritin maintains and promotes the function of regulatory t cells in autoimmunity and cancer. J Immunol. 2016;196:58.12.
   Web of Science ®Google Scholar
• Getts M, Miller S. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol. 2010;160:15–21.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Tadagavadi RK, Swafford D, et al. Modulation of inflammatory responses by Wnt/β-catenin signaling in dendritic cells: a novel immunotherapy target for autoimmunity and cancer. Front Immunol. 2016;7:460.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Abraham C, Flavell RA, et al. Unraveling the genetics of autoimmunity. Cell. 2010;140:791–797.
   PubMed Web of Science ®Google Scholar
• Müllauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res/Rev Mutat Res. 2001;488:211–231.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Rosebeck S, Lucas PC, McAllister-Lucas LM. Protease activity of the API2–MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol. 2011;7:613–617.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431:405–406.
   PubMed Web of Science ®Google Scholar
• Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771–9780.
   PubMed Web of Science ®Google Scholar
• Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007;67:5042–5054.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Goldin LR, Björkholm M, et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94:1581–1589.
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Engels E. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med. 2008;264:537–548.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, van Spronsen DJ, Hooijkaas H, et al. Excess of autoimmune and chronic inflammatory disorders in patients with lymphoma compared with all cancer patients: a cancer registry-based analysis in the south of the Netherlands. Autoimmun Rev. 2011;10:228–234.
   PubMed Web of Science ®Google Scholar
• Vanura K, Späth F, Gleiss A, et al. Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. Ann Hematol. 2011;90:947–954.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:621–631.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica. 2006;91:691–694.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Joseph L, Boivin J, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67:74–79.
   PubMed Web of Science ®Google Scholar
• Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306–1321.
   PubMed Web of Science ®Google Scholar
• Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol. 2009;86:237–250.
   PubMed Web of Science ®Google Scholar
• Kostenko S, Dumitriu G, Lægreid KJ, et al. Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase. WJBC. 2011;2:73–89.
   Google Scholar
• Vara JÁF, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treatment Rev. 2004;30:193–204.
   PubMed Web of Science ®Google Scholar
• Martelli A, Tazzari P, Evangelisti C, et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. CMC. 2007;14:2009–2023.
   PubMed Web of Science ®Google Scholar
• Steelman L, Franklin R, Abrams S, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–1094.
   PubMed Web of Science ®Google Scholar
• Cerutti E, Campagnoli MF, Ferretti M, et al. Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. BMC Immunol. 2007;8:28.
   PubMed Web of Science ®Google Scholar
• Ramenghi U, Bonissoni S, Migliaretti G, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood. 2000;95:3176–3182.
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757–2764.
   PubMed Web of Science ®Google Scholar
• Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017;76:105–111.
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh Y-J. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659:15–30.
   PubMed Web of Science ®Google Scholar
• Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci. 1998;23:74–79.
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? 1. Acta Pharmacol Sin. 2008;29:1275–1288.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35–53.
   PubMed Web of Science ®Google Scholar
• Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010;9:117.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19–26.
   PubMed Web of Science ®Google Scholar
• Kaldis P, Aleem E. Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle. 2005;4:1491–1494.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: twenty-five years later, a golden journey. Blood. 2011;119:651–665.
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Siahaan TJ, Vines CM, et al. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv. 2011;2:873–889.
   PubMedGoogle Scholar
• Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Prev Biomark. 2006;15:2069–2077.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389:1206–1217.
   PubMed Web of Science ®Google Scholar
• Chittasupho C. Multivalent ligand: design principle for targeted therapeutic delivery approach. Ther Deliv. 2012;3:1171–1187.
   PubMedGoogle Scholar
• Chen YJ, Chang YT, Wang CB, et al. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63:352–358.
   PubMedGoogle Scholar
• Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363–367.
   PubMed Web of Science ®Google Scholar
• Kovács L, Szodoray P, Kiss E. Secondary tumours in Sjögren's syndrome. Autoimmun Rev. 2010;9:203–206.
   PubMed Web of Science ®Google Scholar
• Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9–16.
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006;354:942–955.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11:431–437.
   PubMed Web of Science ®Google Scholar
• Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology. 2005;128:S79–S86.
   PubMed Web of Science ®Google Scholar
• Delahunt B, Abernethy D, Johnson C, et al. Prostate carcinoma and the Lambert–Eaton myasthenic syndrome. J Urol. 2003;169:278–279.
   PubMed Web of Science ®Google Scholar
• Horwitz DA, Zheng SG, Gray JD. Natural and TGF-β-induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29:429–435.
   PubMed Web of Science ®Google Scholar
• Lan Q, Fan H, Quesniaux V, et al. Induced Foxp3+ regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol. 2012;4:22–28.
   PubMed Web of Science ®Google Scholar
• Chen Q, Kim YC, Laurence A, et al. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol. 2011;186:6329–6337.
   PubMedGoogle Scholar
• Nguyen T-LM, Sullivan NL, Ebel M, et al. Antigen-specific TGF-β-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. J Immunol. 2011;187:1745–1753.
   PubMed Web of Science ®Google Scholar
• Huter EN, Stummvoll GH, DiPaolo RJ, et al. Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol. 2008;181:8209–8213.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang C, Luo J, et al. Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo. Clin Dev Immunol. 2013;2013:238035.
   PubMedGoogle Scholar
• Lu L, Zhou X, Wang J, et al. Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid. PLoS One. 2010;5:e15150.
   PubMed Web of Science ®Google Scholar
• Qian X, Wang K, Wang X, et al. Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease. Int Immunopharmacol. 2011;11:630–637.
   PubMed Web of Science ®Google Scholar
• Loo K, Daud AI. Inhibitors of cytotoxic T lymphocyte antigen 4 and programmed death 1/programmed death 1 ligand for metastatic melanoma, dual versus monotherapy—summary of advances and future directions for studying these drugs. Cancer J. 2017;23:3–9.
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–2749.
   PubMed Web of Science ®Google Scholar
• Bai L, Lennon DP, Eaton V, et al. Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57:1192–1203.
   PubMed Web of Science ®Google Scholar
• Scherer HU, van Pel M, Toes RE. Mesenchymal stem cells in autoimmune diseases: hype or hope? Arthritis Res Ther. 2010;12:126.
   PubMed Web of Science ®Google Scholar
• Ungerer C, Quade-Lyssy P, Radeke HH, et al. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 2013;23:755–766.
   PubMed Web of Science ®Google Scholar
• Cheng YC, Rondón G, Anderlini P, et al. Paclitaxel and trastuzumab as maintenance therapy in patients with HER2-positive metastatic breast cancer who underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. J Cancer. 2013;4:679.
   PubMed Web of Science ®Google Scholar
• Ben-Ami E, Miller A, Berrih-Aknin S. T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2. Autoimmun Rev. 2014;13:187–196.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Green LK, Zareie P, Templeton N, et al. Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis. Mult Scler J – Exp Transl Clin. 2017;3:2055217317698724.
   Google Scholar
• Zhong W, Zhao L, Liu T, et al. IL-22-producing CD4+ T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. Sci Rep. 2017;7.
   Web of Science ®Google Scholar
• Northrup L, Christopher MA, Sullivan BP, et al. Combining antigen and immunomodulators: emerging trends in antigen-specific immunotherapy for autoimmunity. Adv Drug Deliv Rev. 2016;98:86–98.
   PubMed Web of Science ®Google Scholar
• Wraith D. Autoimmunity: antigen-specific immunotherapy. Nature. 2016;530:422.
   PubMed Web of Science ®Google Scholar
• Flemming A. Autoimmunity: nanoparticles engineered for antigen-specific immunotherapy. Nat Rev Immunol. 2016;16:204–205.
   PubMed Web of Science ®Google Scholar